Investigators in this retrospective cohort study sought to determine long-term outcomes for patients with platinum-sensitive recurrent ovarian cancer who have exceptional response to PARP inhibitors.

Cytokinetics, Incorporated CYTK has entered a pivotal phase following the FDA approval of its first drug, Myqorzo (aficamten) ...

Ōtākou Whakaihu Waka researchers have been part of two studies in the battle against drug resistant strains of Mycobacterium tuberculosis, the cause of tuberculosis. Co-author on both studies, Dr.

Summary: Investigators demonstrated that an experimental compound called BA-101 can successfully strip away glioblastoma’s defensive armor. By selectively blocking an enzyme that fuels the tumor’s ...

Drug has different mechanism of action than existing injectables ...

A new Peter Mac study using a pioneering drug has successfully controlled the growth of tumors and overcome existing drug resistance in multiple cancer types. An enzyme critically associated with ...

When researchers use an inhibitor to block a kinase’s activity, they generally expect to see less of the downstream effects of that kinase. So when neuroscientists observed the opposite using a new ...

The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic ...

Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...

KRAS G12C occurs in ~3%–4% of CRC, translating to a sizable metastatic population with limited options and strong rationale for KRAS G12C inhibition strategies. Dual KRAS–EGFR blockade leverages ...